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Abstract 
Background: Vascular dysfunction is a distinctive phenotype in diabetes mellitus. Current treatments mostly focus 
on the tight glycemic control and few of these treatments have been designed to directly recover the vascular 
dysfunction in diabetes. As a classical natural medicine, berberine has been explored as a possible therapy for DM. In 
addition, it is reported that berberine has an extra‑protective effect in diabetic vascular dysfunction. However, little is 
known whether the berberine treatment could ameliorate the smooth muscle contractility independent of a func‑
tional endothelium under hyperglycemia. Furthermore, it remains unknown whether berberine affects the arterial 
contractility by regulating the intracellular Ca2+ handling in vascular smooth cells (VSMCs) under hyperglycemia.
Methods: Sprague–Dawley rats were used to establish the diabetic model with a high‑fat diet plus injections of 
streptozotocin (STZ). Berberine (50, 100, and 200 mg/kg/day) were intragastrically administered to control and dia‑
betic rats for 8 weeks since the injection of STZ. The intracellular Ca2+ handling of isolated cerebral VSMCs was inves‑
tigated by recording the whole‑cell L‑type Ca2+ channel (CaL) currents, assessing the protein expressions of CaL chan‑
nel, and measuring the intracellular Ca2+ in response to caffeine. Our results showed that chronic administration of 
100 mg/kg/day berberine not only reduced glucose levels, but also inhibited the augmented contractile function of 
cerebral artery to KCl and 5‑hydroxytryptamine (5‑HT) in diabetic rats. Furthermore, chronic administration of 100 mg/
kg/day berberine significantly inhibited the CaL channel current densities, reduced the α1C‑subunit expressions of CaL 
channel, decreased the resting intracellular Ca2+ ([Ca2+]i) level, and suppressed the Ca
2+ releases from RyRs in cerebral 
VSMCs isolated from diabetic rats. Correspondingly, acute application of 10 μM berberine could directly inhibit the 
hyperglycemia‑induced CaL currents and suppress the hyperglycemia‑induced Ca
2+ releases from RyRs in cerebral 
VSMCs isolated from normal control rats.
Conclusions: Our study indicated that berberine alleviated the cerebral arterial contractility in the rat model of 
streptozotocin‑induced diabetes via regulating the intracellular Ca2+ handling of smooth muscle cells.
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Background
Diabetes mellitus (DM) is a kind of metabolic diseases 
characterized by chronic hyperglycemia due to either 
reduced insulin secretion (type 1 DM) or insulin resist-
ance (type 2 DM). DM is also considered to be a kind of 
vascular disorders for diabetic macro- and microvascular 
complications, such as coronary arterial impairment, cer-
ebrovascular injury, and diabetic retinopathy, nephropa-
thy, and neuropathy, are the principal causes of morbidity 
and mortality in patients with type 1 or type 2 DM [1, 2]. 
It has been demonstrated that diabetic vascular compli-
cation is associated with impaired endothelial function, 
augmented vasoconstriction, increased oxidative stress, 
enhanced inflammation, and promoted thrombosis [2]. 
It is believed that hyperglycemia is the hallmark feature 
in the development of diabetic vascular dysfunction and 
so current treatments mostly focus on the tight glyce-
mic control. However, few of these treatments have been 
designed to directly recover the vascular dysfunction in 
diabetes. Because the elevated concentration of intracel-
lular Ca2+ ([Ca2+]i) is the primary stimulus for smooth 
muscle contraction, it is reported that diabetic vascu-
lar dysfunction is tightly coupled to the impairment of 
intracellular Ca2+ handling in vascular smooth muscle 
cells (VSMCs) [3, 4]. Ca2+ influx from the long-lasting 
voltage-dependent Ca2+ (L-type, CaL) channels in plasma 
membrane and Ca2+ releases from the ryanodine recep-
tors (RyRs) in sarcoplasmic reticulum (SR) are the key 
factors to regulate the intracellular Ca2+ in VSMCs [3, 5]. 
An emerging body of evidence from human diabetes and 
different diabetic animal models indicated that hypergly-
cemia induced an increase of [Ca2+]i, promoted the Ca2+ 
influx by the activation of CaL channels, and altered the 
Ca2+ releases from the RyRs in VSMCs [3, 5, 6]. There-
fore, the intracellular Ca2+ handling with their related 
proteins could be an important therapeutic target in dia-
betic vascular complications [3].
Berberine is a classical natural medicine, which has 
been widely used for bacteria-associated diarrhoea and 
other gastrointestinal infections in China [7]. In recent 
years, the herbal compound berberine has been explored 
as a possible therapy in DM for its metabolic activities 
of lowing blood glucose and regulating lipids, which has 
been studied and evidenced in the treatment of human 
diabetes and animal diabetic models [8, 9]. In addition, 
extensive research demonstrated that berberine treat-
ment also had a cardiovascular protective effect in dia-
betic nephropathy, diabetic neuropathy, and diabetic 
cardiomyopathy [10–12]. For example, the berberine 
treatment was found to ameliorate diabetic endothe-
lium-dependent relaxation by reducing oxidative stress 
and inflammatory response [10, 13–15]. It is believed 
that hyperglycemia may injury vascular function at both 
endothelium level and smooth muscle cell layers [2, 
3]. However, previous researches on berberine mostly 
focused on the endothelial cells in the treatment of dia-
betic vascular dysfunction. Little is known whether the 
berberine treatment could ameliorate the smooth mus-
cle contractility independent of a functional endothelium 
under hyperglycemia. Furthermore, it remains unknown 
whether berberine affects the smooth muscle contrac-
tility by regulating the intracellular Ca2+ handling in 
VSMCs under hyperglycemia.
The purpose of the present study was (1) to investi-
gate the effects of berberine treatment on cerebrovas-
cular contractile function independent of a functional 
endothelium in streptozotocin (STZ)-induced diabetic 
rats; (2) to investigate the effects of berberine on the 
intracellular Ca2+ handling of cerebral VSMCs in dia-
betic rats or when exposed to hyperglycemia condition, 
such as recording the whole-cell CaL currents, assess-
ing the protein expressions of CaL channel, and measur-
ing the intracellular Ca2+ in response to caffeine. Taken 
together, the present study provided initial evidences that 
berberine alleviates the cerebrovascular contractile func-
tion directly by the inhibition of CaL channels and the 
suppression of Ca2+ releases from the RyRs in cerebral 
VSMCs of streptozotocin-induced diabetic rats.
Methods
All animal procedures described in this study were in 
adherence with the Guide for the Care and Use of Labo-
ratory Animals published by the US National Institutes 
of Health (NIH Publication No. 85–23, revised 1996), 
with approval from Committee on the Ethics of Animal 
Experiments of the University of Xi’an Jiaotong Uni-
versity. In addition, the animal research performed in 
the present study was in compliance with the ARRIVE 
(Animals in Research: Reporting In  Vivo Experiments) 
guidelines [16]. All surgery was performed under sodium 
pentobarbital anesthesia, and all efforts were made to 
minimize suffering unless otherwise stated, all chemi-
cals and reagents used in this study were obtained from 
Sigma Chemical Company (St. Louis, Missouri, USA).
Animal model
Male Sprague–Dawley rats (~190  g) used in this study 
were purchased from Medical Laboratory Animal 
Center of Xi’an Jiaotong University. After an adaptive 
feeding for 1  week, the SD rats were randomly divided 
into two groups: diabetic rats and control rats. The dia-
betic rat model was established with a high-fat diet 
plus injections of STZ, which was described previously 
[13, 17]. The high-fat diet consisted of 70  % standard 
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laboratory chow, 5 % yolk powder, 10 % lard, 15 % car-
bohydrate. The control rats were given the regular diet. 
Following 4  weeks of dietary intervention, the diabetic 
rats were injected intraperitoneally with 45 mg/kg STZ 
for consecutively twice in 2 days, which was freshly dis-
solved in 0.1  M sodium citrate buffer (pH 4.5–5.0). In 
contrast, the control rats were injected intraperitoneally 
with vehicle citrate buffer in a dose volume of 1 ml/kg. 
Blood samples were collected by tail cutting for fasting 
blood glucose measurements by glucose oxidase/peroxi-
dase method. Mean values of the fasting serum insulin 
level were measured by radioimmunoassay method. Suc-
cessful induction of diabetes was considered as sustained 
fasting blood glucose levels >11.1 mM at 72 h after STZ-
injection. Failed induction of diabetes was excluded dur-
ing the whole study. The present study was divided into 
three experiments: Experiment I, Experiment II, and 
Experiment III. Experiment I was designed to investigate 
the effects of 100  mg/kg/day berberine on the contrac-
tile function of cerebral artery, the function of CaL chan-
nel, and the intracellular Ca2+ in response to caffeine in 
STZ-induced diabetic rats. Experiment II and Experi-
ment III were designed to investigate the effects of 50 
and 200 mg/kg/day berberine on the contractile function 
of cerebral artery, the function of CaL channel, and the 
intracellular Ca2+ in response to caffeine in STZ-induced 
diabetic rats. In Experiment I, rats were divided into four 
groups (n = 20/group): control rats (CON), control rats 
administered with berberine chloride (CON + 100 mg/
kg/day berberine), diabetic rats, and diabetic rats admin-
istered with berberine chloride (Diabetic + 100 mg/kg/
day berberine). In Experiment II and Experiment III, 
rats were divided into four groups (n = 10/group): con-
trol rats (CON), control rats administered with 50 or 
200 mg/kg/day berberine chloride, diabetic rats, and dia-
betic rats administered with 50 or 200  mg/kg/day ber-
berine chloride, respectively. After that, the diabetic and 
control rats were fed on the high-fat diet and the regular 
diet for another 8 weeks, respectively. Berberine chloride 
were dissolved and then intragastrically administered 
daily for 8 weeks. The other groups received equal vol-
ume of vehicles. The intragastric dose of berberine in 
this study was used according to our pre-experiments 
and the previous reports that the dose of 100 mg/kg/day 
is more close to the clinical practice than veno-injection 
or intraperitoneal administration [13, 18]. Eight weeks 
after the berberine treatment, animals were anesthetized 
with pentobarbital sodium (50  mg/kg ip) and killed by 
exsanguinations via the abdominal aorta. Body weight 
and fasting blood glucose were measured every week for 
monitoring diabetic condition. All groups were caged 
individually in a room maintained at 23 °C on a 12:12-h 
light–dark cycle and received water ad libitum.
Examination of contractile function
As previously described [19], the segment of middle cere-
bral artery was transferred to the PSS containing (in mM): 
119 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 
2.5 CaCl2, 5.5 glucose, and 0.026 EDTA, equilibrated with 
21 % O2, 5 % CO2, and 74 % N2 at pH 7.4 adjusted with 
NaOH. The endothelial layer was mechanically removed 
by the injection of air bubbles and then cannulated by 
two pipettes with nylon suture in a vessel chamber. After 
cannulation, the chamber was transferred to the Pressure 
Myograph System P110 (DMT, Denmark) and the arterial 
segment was perfused under a pressure of 25 mmHg for 
5–10 min to check the leaking and then remove the blood 
residue. The arterial segment was allowed to equilibrate 
at 37  °C and 50  mmHg for 1  h. After equilibration, the 
arterial viability was evaluated by its reactivity to 20 and 
60 mM isotonic KCl. Then the pressure was cycled three 
times between 25 and 125 mmHg to reduce mechanical 
hysteresis. To determine the contractile function, con-
centration–response relationships were determined by 
the cumulative superfusion of isotonic KCl (0–100 mM) 
and 5-hydroxytryptamine (5-HT, 10−10–10−4  M) while 
the arteries were pressurized at 50 mmHg in Ca2+-con-
tained PSS. Contractile response to cumulative superfu-
sion of KCl or 5-HT was represented as the percentage of 
luminal diameter relative to the baseline internal diam-
eter according to the formula: luminal diameter change 
(%) = (Di,a,s−Di,a,b)/Di,a,b × 100 %, where Di,a,b is the 
baseline internal diameter measured in active state at a 
pressure of 50 mmHg and Di,a,s is the steady-state inter-
nal diameter measured to each subsequent change in 
agonist concentration at the same pressure.
Isolation of VSMCs
Enzymatic isolation of single VSMC was carried out 
as previously described [20]. Briefly, brain tissues were 
removed rapidly and placed in 4  °C physiological salt 
solution (PSS) which contained (in mM) 137 NaCl, 
5.6 KCl, 1 MgCl2, 0.42 Na2HPO4, 0.44 NaH2PO4, 4.2 
NaHCO3, and 10 HEPES, equilibrated with 95 % O2 and 
5 % CO2 at pH adjusted to 7.4 with NaOH. The cerebral 
arteries including superior, middle, and basilar arter-
ies with the circle of Willis were dissected and digested 
for 18  min at 37  °C with the solution contained 4  mg/
ml papain (Biochrom, Berlin, Germany), 2 mg/ml dithi-
oerythritol (Amresco, St. Louis, Missouri, USA), 1 mg/ml 
bovien serum albumin (BSA), and 5 mM taurine in PSS. 
Arterial segments were then transferred to enzyme-free 
PSS containing 1 mg/ml BSA and 5 mM taurine at room 
temperature for 10 min and triturated with a flame-pol-
ished pipette to disperse VSMCs. Isolated VSMCs were 
suspended in Ca2+-free PSS containing 1 mg/ml BSA and 
5 mM taurine and stored at 4 °C for use within 8 h.
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Electrophysiological measurements
As previously described [21], patch-clamp recordings 
were performed with an amplifier (CEZ-2300, Nihon 
Kohden Co., Tokyo, Japan), a version interface (Axon 
Instruments, Foster City, California, USA), and the 
pCLAMP software (version 8.0, Axon Instruments). 
Patch pipettes (tip resistance 2–6  MΩ) were fabricated 
on an electrode puller (Narishige Instruments, Tokyo, 
Japan). Whole-cell CaL channel currents were meas-
ured with the conventional voltage clamp configuration. 
Cell capacitance (Cm) was estimated from the capacitive 
current transient evoked by applying a 20-mV pulse for 
40  ms from a holding potential of −60 to −40  mV. The 
cell was held at −40 mV and then stepped in 10-mV incre-
ments from −30 to +60 mV. Voltage steps were 250 ms 
in duration with 2-s intervals between steps. Nonspecific 
membrane leakage and residual capacitive currents were 
subtracted using the P/4 protocol. Currents were sampled 
and averaged while the current amplitude was stabilized. 
Barium (Ba2+) was used as the charge carrier to increase 
unitary currents. Currents were normalized to Cm to 
obtain the current densities. To obtain the I–V curve of 
CaL, the current densities were plotted against the cor-
responding command potentials. Two kinds of external 
solutions were used, i.e., solution A and B. Solution A was 
used while making a gigaohm seal between the recording 
pipette and cell surface. It contained (in mM) 130 NaCl, 
5.4 KCl, 1 MgCl2, 10 BaCl2, 10 HEPES, and 10 glucose, 
equilibrated with 95 % O2 and 5 % CO2 at pH 7.4 adjusted 
with NaOH. After a seal of 2 GΩ was obtained, the per-
fusion fluid was changed to solution B before current 
recording. It contained (in mM) 75 Tris–Cl, 50 BaCl2, 10 
HEPES, and 10 glucose, equilibrated with 95 % O2 and 5 % 
CO2 at pH 7.4 titrated with Tris base. The pipette solu-
tion contained 150 CsCl, 1 MgCl2, 10 EGTA, 5 HEPES, 5 
Na2ATP, and 5 Na2 creatine phosphate, equilibrated with 
95  % O2 and 5  % CO2 at pH 7.2 titrated with CsOH. In 
the present study, extracellular application of 5 μM Bay K 
8644 (the specific agonist of CaL) and 0.1 μM nifedipine 
(the specific blocker of CaL) were used to identify the 
properties of CaL as described before [21]. All measure-
ments were performed at room temperature (22–24 °C).
Evaluation of CaL channel protein expression by Western 
blotting
According to our previous report [21], cerebral arter-
ies were minced into small pieces and homogenized on 
ice containing tissue protein extraction reagent (T-PER, 
Pierce, Rockford, Illinois, USA) and protease inhibitor 
(Halt, Pierce, Rockford, Illinois, USA). Large tissue debris 
and nuclear fragments were removed by two centrifuge 
spins (1000 rpm for 5 min, 12,000 rpm for 15 min) at 4 °C 
and supernatants were obtained. The concentration of 
protein sample was determined by the bicinchoninic acid 
method (Pierce, Rockford, Illinois, USA) using BSA as 
a standard. Equivalent amounts of proteins from differ-
ent groups were loaded to adjacent lanes for SDS-PAGE. 
Protein samples were run for 80  min at 30  mA for an 
electrophoretic size-separation using a 8  % Tris–Glycine 
gel (Invitrogen, Carlsbad, California, USA). After size 
separation, proteins were transferred onto a nitrocellu-
lose membrane at 100 mA for 3 h and blocked with 5 % 
nonfat dry milk in PBS containing 0.1 % (w/v) Tween 20 
(PBS-T) overnight at 4  °C. Subsequently, the membranes 
were incubated for 3 h with a 1:200 dilution of rabbit poly-
clonal antibody against amino acids 848–865, which corre-
sponds to the C-terminus site of CaL channel α1C-subunit 
(Alomone Labs, Jerusalem, Israel). The membrane then 
incubated for 45 min with Infrared (IR)-labeled secondary 
antibodies (LI-COR) in PBS-T containing 0.01 % SDS. A 
monoclonal mouse antibody raised against the structural 
protein β-actin (Sigma) was used as a lane-loading control. 
The bound antibody was detected by the Odyssey infrared 
imaging system (LI-COR), and the densities of immunore-
active band were expressed as a percentage of the β-actin 
density for each lane. Densitometry analysis of bands was 
performed by Scion image (Scion, Frederick, MD).
Measurement of intracellular Ca2+ in response to caffeine
As previously described [21], we investigated the aver-
age changes of intracellular Ca2+ fluorescence intensity 
with Ca2+ indicator, Fluo-3-acetoxymethyl ester (Fluo-3/
AM, Molecular Probes, Oregon, USA). Isolated cer-
ebral VSMCs were incubated with Fluo-3/AM in a final 
concentration of 5  μM for 30  min at 37  °C. Then, the 
Fluo-3/AM-loaded cells were washed with Ca2+-free 
balanced salt solution (BSS) which contained (mM) 126 
NaCl, 5 KCl, 0.3 NaH2PO4, 10 HEPES, 1 MgCl2, 10 glu-
cose, 1 EGTA, equilibrated with 95  % O2 and 5  % CO2 
at pH 7.4 adjusted with NaOH. The cells were scanned 
under a laser confocal microscope (Olympus FV1000, 
Tokyo, Japan) by illuminating with a krypton/argon laser 
at 488 nm emitted light and capturing the emitting fluo-
rescence at 526 nm. To ensure efficient quantum capture, 
the cells were placed on the bottom of a recording cham-
ber and images were recorded after 10–20 s when fluo-
rescence intensity became stable. During continuously 
scanning, 10 mM caffeine in Ca2+-free BSS was adminis-
trated to the cell and a period of 3 min was recorded. To 
avoid any laser-induced change in Ca2+ signaling, each 
cell was scanned only once. The average fluorescence 
intensity was used to indicate the changes of intracellular 
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Ca2+. The maximal increase of Ca2+ fluorescence inten-
sity was used to indicate the function of ryanodine-sensi-
tive Ca2+ releases from SR in VSMCs.
Statistical analysis
Except the data of body weight are given as mean ±  SD, 
all other data are expressed as mean  ±  SEM. One-way 
ANOVA was used to determine the differences of CaL 
channel current densities in different groups, followed by a 
S–N–K-Post Hoc. Student’s t test was used to determine sig-
nificant differences of body weights, blood glucose, the rest-
ing Ca2+ fluorescence intensity, and the maximal increase of 
Ca2+ fluorescence intensity in different groups. A value of 
P ≤ 0.05 was considered to be statistically significant.
Results
Physical characteristics of experimental animals
The rat model of STZ-induced diabetes is well-established 
using a toxin to destroy the pancreatic β-cells. As com-
pared with control rats, the levels of blood glucose sig-
nificantly increased and the body weights significantly 
decreased in diabetic rats from 4 to 8  week after STZ-
injection, respectively, which indicated that diabetic rat 
model has been established successfully [13, 18]. In Experi-
ment I, when the diabetic rats were treated with 100 mg/
kg/day berberine for 4 or 8  weeks, there were a marked 
decrease in the blood glucose and an obvious increase 
in the body weight of diabetic rats, respectively, which is 
well in accordance with earlier studies [13, 18]. However, 
there were also the significant differences in the blood glu-
cose and body weight between Diabetic + berberine and 
CON rats, which indicated that berberine treatment did 
not restore the blood glucose and body weight of diabetic 
rats to the normal control level (Table 1). When the con-
trol rats were treated with 100 mg/kg/day berberine, there 
was only a declined tendency and no significant differ-
ence both in the blood glucose and body weight between 
CON + berberine and CON rats. In addition, as shown in 
Table 2, diabetic rats showed a drastic increase in serum 
insulin level as compared with the normal control group, 
which is similar to previous report [13]. After 8 weeks of 
treatment of 100  mg/kg/day berberine, serum insulin 
levels also significantly decreased in diabetic rats. These 
results indicated that 100 mg/kg/day berberine treatment 
obviously has a hypoglycemic effect in diabetic rats.
In Experiment II and Experiment III, when the dia-
betic rats were treated with 50 mg/kg/day berberine for 
8 weeks, there were no obvious effects on blood glucose 
and body weight in CON and diabetic rats, respectively. 
However, 200  mg/kg/day berberine for 8  weeks signifi-
cantly decreased blood glucose in both CON and diabetic 
rats (Table 3).
Chronic treatment of 100 mg/kg/day berberine 
significantly inhibited the augmented contractile function 
of middle cerebral artery in diabetic rats
In the present study, removal of the endothelial layer was 
used to rule out the endothelium-dependent relaxation, 
which may affect the contractile responses of VSMCs. 
As compared with that in CON, contractile responsive-
ness of middle cerebral artery to KCl (Fig. 1a) and 5-HT 
(Fig.  1b) were both significantly increased in diabetic 
rats, which is in accordance with previous report [22]. 
In Experiment I, chronic administration of berberine 
Table 1 Body weight and  fasting blood glucose in  CON, CON  +100  mg/kg/day berberine, diabetic, and  dia-
betic +100 mg/kg/day berberine rats at 4 and 8 weeks after STZ-injection in Experiment I
CON control rats, CON + berberine control rats administrated with berberine (100 mg/kg/day), Diabetic diabetic rats, diabetic + berberine diabetic rats administrated 
with berberine (100 mg/kg/day). * P < 0.05 vs. CON and # P < 0.05 vs. diabetic rats
Initial 4 Week after STZ-injection 8 Week after STZ-injection
Body weight (g) Blood glucose (mM) Body weight (g) Blood glucose (mM) Body weight (g) Blood glucose (mM)
CON (n = 20) 195.0 ± 25.7 4.2 ± 1.2 423.5 ± 55.8 5.2 ± 0.9 501.0 ± 75.6 5.6 ± 1.5
CON + berberine 
(n = 20)
186.5 ± 28.1 3.8 ± 2.2 417.9 ± 65.3 4.1 ± 1.2 483.5 ± 72.1 4.5 ± 1.7
Diabetic (n = 20) 190.0 ± 23.4 3.6 ± 1.3 270.3 ± 46.3* 21.9 ± 5.4* 251.0 ± 52.7* 25.91 ± 6.6*
Diabetic + berberine 
(n = 20)
187.0 ± 25.5 4.1 ± 1.6 327.0 ± 51.2#,* 16.5 ± 4.5#,* 353.0 ± 58.3#,* 14.8 ± 4.3#,*
Table 2 Mean values of  the serum insulin level in  CON, 
CON  +100  mg/kg/day berberine, diabetic, and  dia-
betic +100 mg/kg/day berberine rats at 8 weeks after STZ-
injection in Experiment I
CON control rats, CON + berberine control rats administrated with berberine 
(100 mg/kg/day), Diabetic diabetic rats, diabetic + berberine diabetic rats 
administrated with berberine (100 mg/kg/day). * P < 0.05 vs. CON and  # P < 0.05 
vs. diabetic rats
Group Insulin (μIU/ml)
CON (n = 20) 9.0 ± 1.5
CON + berberine (n = 20) 8.7 ± 1.7
Diabetic (n = 20) 13.6 ± 1.8*
Diabetic + berberine (n = 20) 11.5 ± 1.2#,*
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(100  mg/kg/day) for 8  weeks significantly inhibited the 
augmented contractile responsiveness of middle cerebral 
artery to KCl (Fig. 1a) and 5-HT (Fig. 1b) in diabetic rats, 
respectively. For example, when the concentration of KCl 
was 60  mM, 100  mg/kg/day berberine treatment could 
markedly reduce the relative changes of luminal diameter 
from (−36.5 ± 3.2) % in diabetic rats to (−30.8 ± 3.0) % 
in diabetic +  berberine rats (Fig.  2a). In addition, when 
the concentration of 5-HT was 10−6 M, 100  mg/kg/day 
berberine treatment could significantly decrease the rela-
tive changes of luminal diameter from (−42.5 ± 3.7) % in 
diabetic rats to (−35.9 ±  3.3)  % in diabetic +  berberine 
rats (Fig.  2b). However, there was also a significant dif-
ference in the contractile responsiveness of middle cer-
ebral artery between Diabetic + berberine and CON rats, 
which indicated that berberine treatment did not restore 
the contractile responsiveness of middle cerebral artery in 
diabetic rats to the normal control level. When the control 
rats were treated with berberine (100  mg/kg/day), there 
was no significant difference in the contractile respon-
siveness of middle cerebral artery between CON +  ber-
berine and CON rats. These results clearly suggested that 
100 mg/kg/day berberine treatment significantly inhibited 
the augmented contractile function of middle cerebral 
artery in diabetic rats.
In Experiment II and Experiment III, chronic treat-
ment with 50  mg/kg/day berberine for 8  weeks had no 
obvious effects on contractile responsiveness in CON 
and Diabetic rats, respectively. However, 200 mg/kg/day 
berberine for 8  weeks significantly inhibited contractile 
responsiveness in both CON and diabetic rats (Fig. 2).
Chronic administration of 100 mg/kg/day berberine 
markedly inhibited the increased CaL current densities 
of cerebral VSMCs in diabetic rats
To evaluate the function of CaL channels, whole-cell cur-
rents were recording with conventional patch clamp 
techniques. As shown in Fig.  3a, the typical time- and 
voltage-dependent inward currents were evoked by 
increasing depolarizations from a holding potential of 
−40 mV to +60 mV. The mean current–voltage relation-
ship (I–V) curves which were further expressed in terms 
of current densities which were calculated by normal-
izing current to Cm (Fig.  3b) [20]. Whole-cell CaL cur-
rents of cerebral VSMCs in diabetic rats showed a larger 
inward components of trace as compared with that in 
CON (Fig.  3a), which is consistent with the previous 
reports [5, 22]. In Experiment I, chronic administration 
of berberine (100  mg/kg/day) for 8  weeks significantly 
inhibited the increased CaL channel current densities of 
cerebral VSMCs in diabetic rats. However, there was also 
a significant difference in CaL channel current densities 
of cerebral VSMCs between Diabetic  +  berberine and 
CON rats, which indicated that berberine treatment did 
not restore the CaL channel current densities of cerebral 
VSMCs to the normal control level. When the control rats 
were treated with berberine (100 mg/kg/day), there was no 
significant difference in the CaL channel current densities 
of cerebral VSMCs between CON + berberine and CON 
rats. These results clearly suggested that 100  mg/kg/day 
berberine treatment significantly inhibited the increased 
CaL channel current densities of cerebral VSMCs isolated 
from diabetic rats.
Table 3 Body weight and fasting blood glucose in CON, CON +50 or 200 mg/kg/day berberine, diabetic, and diabetic +50 
or 200 mg/kg/day berberine rats at 8 weeks after STZ-injection in Experiment II and Experiment III
CON control rats, CON + berberine control rats administrated with berberine, Diabetic diabetic rats, diabetic + berberine diabetic rats administrated with berberine. 
* P < 0.05 vs. CON and  # P < 0.05 vs. diabetic rats
Initial 8 Week after STZ-injection
Body weight (g) Blood glucose (mM) Body weight (g) Blood glucose (mM)
Experiment II
 CON (n = 10) 187.0 ± 22.8 4.9 ± 1.8 493.0 ± 55.2 5.2 ± 2.3
 CON +50 mg/kg/day berberine (n = 10) 190.5 ± 18.3 4.3 ± 2.0 511.5 ± 62.1 5.7 ± 2.1
 Diabetic (n = 10) 189.0 ± 17.6 4.6 ± 1.9 253.0 ± 72.7* 19.9 ± 4.9*
 Diabetic +50 mg/kg/day berberine (n = 10) 191.0 ± 18.5 4.9 ± 2.5 261.0 ± 68.7#,* 18.2 ± 5.3*
Experiment III
 CON (n = 10) 195.0 ± 23.1 4.5 ± 1.2 503.0 ± 47.9 5.6 ± 1.2
 CON +200 mg/kg/day berberine (n = 10) 196.5 ± 18.6 3.9 ± 2.5 406.5 ± 57.2* 3.7 ± 1.1*
 Diabetic (n = 10) 200.0 ± 21.7 4.3 ± 1.8 296.0 ± 82.1* 18.8 ± 4.5*
 Diabetic +200 mg/kg/day berberine (n = 10) 192.0 ± 17.8 4.4 ± 1.6 381.0 ± 55.8# 10.2 ± 3.7#,*
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In Experiment II and Experiment III, chronic treatment 
with 50  mg/kg/day berberine for 8  weeks had no obvi-
ous effects on CaL channel function in CON and diabetic 
rats, respectively. However, 200 mg/kg/day berberine for 
8  weeks significantly inhibited CaL channel function in 
both CON and diabetic rats (Fig. 4).
Chronic administration of 100 mg/kg/day berberine 
significantly reduced the augmented α1C-subunit 
expressions of CaL channel in cerebral arteries isolated 
from diabetic rats
The apparent masses of 240 kD band were shown in the 
membrane, which correspond to the predicted sizes of 
α1C-subunit protein of CaL channel in cerebral arteries 
[21]. As the internal control, the expressions of β-actin 
(42  kDa) were similar in different lanes in the bottom 
membrane, showing the equal protein loading (Fig.  5a). 
The averaged data was expressed as the percentage of 
β-actin signal (Fig.  5b). As compared with that in CON 
rats, α1C-subunit expressions of CaL channel significantly 
increased in cerebral arteries of diabetic rats. In Experi-
ment I, chronic administration of berberine (100 mg/kg/
day) for 8  weeks significantly reduced the augmented 
α1C-subunit expressions of CaL channel in cerebral arter-
ies of diabetic rats. However, there was also a significant 
difference in the α1C-subunit expressions of CaL channel 
in cerebral arteries between Diabetic  +  berberine and 
CON rats, which indicated that berberine treatment did 
not restore the α1C-subunit expressions of CaL channel 
in cerebral arteries of diabetic rat to the normal control 
level. When the control rats were treated with berber-
ine (100 mg/kg/day), there was no significant difference 
in the α1C-subunit expressions of CaL channel in cerebral 
arteries between CON + berberine and CON rats. These 
results suggested that berberine treatment significantly 
reduced the augmented α1C-subunit expressions of CaL 
channel in cerebral arteries isolated from diabetic rats.
Chronic administration of 100 mg/kg/day berberine not 
only markedly decreased the increased resting [Ca2+]i 
level, but also suppressed the augmented Ca2+ releases 
from RyRs in cerebral VSMCs isolated from diabetic rats
As previously described [21], a high concentration of 
caffeine (10  mM) was used to activate RyRs and then 
evoked a transient peak increase of [Ca2+]i which rep-
resents the Ca2+ release from the SR. Representa-
tive dot graph of Fluo-3/AM fluorescence recorded 
showed the typical transient increases of intracellu-
lar Ca2+ fluorescence intensity evoked by 10  mM caf-
feine (Fig. 6A). Summarized data indicated the average 
changes of the intracellular Ca2+ fluorescence intensity 
before and during the application of caffeine (Fig.  6B). 
We investigated the resting [Ca2+]i level and the maxi-
mal caffeine-induced increases of [Ca2+]i in cerebral 
VSMCs isolated from CON, CON  +  berberine, Dia-
betic, and Diabetic  +  berberine rats. As compared 
a
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Fig. 1 Comparison of contractile response in middle cerebral artery 
to cumulative superfusion of KCl (a) and 5‑hydroxytryptamine 
(5‑HT, b) in CON, CON +100 mg/kg/day berberine, diabetic, and 
diabetic +100 mg/kg/day berberine rats. Concentration–response 
relationships of middle cerebral artery were represented as the 
percentage of luminal diameter relative to the baseline internal 
diameter. Chronic administration of 100 mg/kg/day berberine 
significantly inhibited the augmented contractile responsiveness to 
KCl (a) and 5‑HT (b) in diabetic rats, respectively. CON control rats, 
CON + berberine control rats administrated with berberine (100 mg/
kg/day), Diabetic diabetic rats, diabetic + berberine: diabetic rats 
administrated with berberine (100 mg/kg/day). Values are expressed 
as mean ± SEM and n = 8 animals in each group. *P < 0.05 vs. CON 
rats and #P < 0.05 vs. diabetic rats
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with that of CON rats, there is a significant higher rest-
ing [Ca2+]i level in cerebral VSMCs isolated from dia-
betic rats, which is consistent with previous report that 
high glucose contributes to elevate the global [Ca2+]i in 
VSMCs [4, 5]. The maximal increases of [Ca2+]i were 
also significantly increased in cerebral VSMCs isolated 
from diabetic rats as compared with that of CON rats. 
In Experiment I, chronic administration of berber-
ine (100  mg/kg/day) for 8  weeks not only significantly 
decreased the resting [Ca2+]i level, but also markedly 
suppressed the maximal increases of [Ca2+]i in cerebral 
VSMCs isolated from diabetic rats. However, there were 
also significant differences in the resting [Ca2+]i level 
and the maximal increases of [Ca2+]i in cerebral VSMCs 
between diabetic  +  berberine and CON rats, which 
indicated that berberine treatment did not restore the 
resting [Ca2+]i level and the Ca2+ releases from RyRs in 
cerebral VSMCs of diabetic rats to the normal control 
level. When the control rats were treated with berber-
ine (100 mg/kg/day), there was no significant difference 
in the resting [Ca2+]i level and the Ca2+ releases from 
RyRs in cerebral VSMCs between CON  +  berberine 
and CON rats. These results indicated that berberine 
treatment not only markedly decreased the increased 
resting [Ca2+]i level, but also suppressed the augmented 
Ca2+ releases from RyRs in cerebral VSMCs isolated 
from diabetic rats.
In Experiment II and Experiment III, chronic treatment 
with 50 mg/kg/day berberine for 8 weeks had no obvious 
effects on maximal increases of Ca2+ fluorescence inten-
sity in CON and diabetic rats, respectively. However, 
200 mg/kg/day berberine for 8 weeks significantly inhib-
ited maximal increases of Ca2+ fluorescence intensity in 
both CON and diabetic rats (Fig. 7).
Acute application of berberine directly inhibited the 
hyperglycemia-induced CaL currents in cerebral VSMCs 
isolated from normal rats
To determinate whether the inhibition of CaL channel in 
diabetic rats is mainly due to a direct effect of berberine 
or only a secondary consequence of the lowing blood glu-






































   
   















































   
   














































   
   














































   
   
















































   
   














































   
   









 50 mg/kg/d Berberine
Fig. 2 Comparison of contractile function in response to different dose of berberine (50, 100 and 200 mg/kg/day) at 60 mM KCl (a) and 10−6 M 
5‑hydroxytryptamine (5‑HT, b) in middle cerebral artery isolated from CON, CON + berberine, Diabetic, and diabetic + berberine rats, respectively. 
Chronic administration of 50 mg/kg/day berberine had no obvious effects on contractile responsiveness to KCl (a) and 5‑HT (b) in CON and diabetic 
rats, respectively. However, chronic administration of 100 mg/kg/day berberine did not change the contractile responsiveness in CON rats, whereas 
significantly inhibited the augmented contractile responsiveness to KCl (a) and 5‑HT (b) in diabetic rats, respectively. In addition, chronic admin‑
istration of 200 mg/kg/day berberine significantly inhibited the contractile responsiveness to KCl (a) and 5‑HT (b) in both CON and diabetic rats, 
respectively. CON control rats, CON + berberine control rats administrated with different dose of berberine, Diabetic diabetic rats, diabetic + berber‑
ine: diabetic rats administrated with different dose of berberine. Values are expressed as mean ± SEM and n = 8 animals in each group. *P < 0.05 vs. 
CON rats and #P < 0.05 vs. diabetic rats
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the acute effects of berberine on the function of CaL chan-
nel in cerebral VSMCs isolated from normal control rats 
under high glucose condition. As shown in Fig. 5, extra-
cellular application of the high glucose (d-glucose, 20 mM 
for 2–7  min, as described previously [5]) significantly 
evoked an increase of CaL channel currents at +10  mV 
test potential. Subsequently, acute extracellular applica-















































 CON+100 mg/kg/d Berberine (n=12)
 Diabetic (n=16)
 Diabetic+100 mg/kg/d Berberine (n=13)
Fig. 3 Comparison of whole‑cell CaL current density in cerebral VSMCs isolated from CON, CON +100 mg/kg/day berberine, Diabetic, and 
diabetic +100 mg/kg/day berberine rats. Representative recording traces were used to show the whole‑cell CaL currents (a) and the mean I–V 
curves were further expressed in terms of current densities (b) in different groups. Chronic administration of 100 mg/kg/day berberine markedly 
inhibited the increased CaL channel current density of cerebral VSMCs in diabetic rats. CON control rats, CON + berberine control rats administrated 
with berberine (100 mg/kg/day), Diabetic diabetic rats, diabetic + berberine: diabetic rats administrated with berberine (100 mg/kg/day). Values are 
mean ± SEM with the number of cells recorded in parentheses. *P < 0.05 vs. CON rats and #P < 0.05 vs. diabetic rats
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markedly reduced the amplitude of the inward currents 
in the presence of 20 mM d-glucose. These findings sug-
gested that hyperglycemia increased CaL channel current 
and then the acute extracellular application of berberine 
could directly reduced the hyperglycemia-induced CaL 
currents in cerebral VSMCs of normal control rats.
Acute application of berberine directly suppressed the 
hyperglycemia-induced Ca2+ releases from RyRs in cerebral 
VSMCs isolated from normal rats
To determinate whether the suppression of Ca2+ releases 
from RyRs diabetic rats is mainly due to a direct effect of 
berberine or only a secondary consequence of the low-
ing blood glucose in response to berberine treatment, we 
investigated the acute effects of berberine on the Ca2+ 
releases from RyRs in cerebral VSMCs isolated from 
normal control rats under high glucose condition. After 
the load of Fluo-3/AM, the isolated VSMCs were incu-
bated with 20 mM d-glucose and the combination of 10 
μM berberine and 20 mM d-glucose for 10 min at 37 °C, 
respectively. As shown in Fig. 6, incubation with 20 mM 
d-glucose significantly increased the resting [Ca2+]i level 
(Fig. 6Ba) and maximal increases of [Ca2+]i fluorescence 
intensity (Fig. 6Bb). However, incubation with combina-
tion of 10 μM berberine and 20 mM d-glucose markedly 
suppressed the resting [Ca2+]i level (Fig. 6Ba) and maxi-
mal increases of [Ca2+]i fluorescence intensity (Fig. 6Bb). 
These findings suggested that hyperglycemia increased 
the resting [Ca2+]i and Ca2+ releases from RyRs and then 
the acute application of berberine could directly reduced 
the hyperglycemia-induced Ca2+ releases from RyRs in 
cerebral VSMCs of normal control rats.
Discussion
There are two principal and novel findings in the pre-
sent work. First, the berberine treatment could inhibit 
the increased cerebrovascular contractility independent 
of a functional endothelium in the rat model of strepto-
zotocin-induced diabetes. Secondly, the berberine treat-
ment not only inhibited the function of CaL channel, but 
also suppressed the Ca2+ releases from the RyRs of cer-
ebral VSMCs in diabetic rats or when exposed to hyper-
glycemia condition. Our study indicated that berberine 
alleviated the cerebral arterial contractility in the rat 
model of streptozotocin-induced diabetes via regulating 
the intracellular Ca2+ handling of smooth muscle cells.
Hyperglycemia impaired the intracellular Ca2+ handling 
in diabetic vascular dysfunction
Diabetic vascular complication has been demonstrated 
to be not only responsible for the increased risk of stroke 
and heart attack, but also contribute to the diabetic organ 
damage in diabetic patients [3]. Under diabetic condi-
tions, multiple factors may intend to impair the function 
and structure of artery, including hyperglycemia, insu-
lin resistance, hyperinsulinemia, excess free fatty acid 
(FFAs) release, advanced glycation end products (AGEs), 
lipemia, and obesity [1, 2]. However, hyperglycemia is 
still considered to be the most important feature in the 
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 200 mg/kg/d Berberine
Fig. 4 Comparison of CaL peak current density in response to different dose of berberine (50, 100 and 200 mg/kg/day) in cerebral VSMCs isolated 
from CON, CON + berberine, diabetic, and diabetic + berberine rats. Chronic administration of 50 mg/kg/day berberine had no obvious effects 
on CaL peak current density in CON and diabetic rats, respectively. However, chronic administration of 100 mg/kg/day berberine did not change 
the CaL peak current density in CON rats, whereas significantly inhibited the augmented CaL peak current density in diabetic rats, respectively. In 
addition, chronic administration of 200 mg/kg/day berberine significantly inhibited the CaL peak current density in both CON and diabetic rats, 
respectively. CON control rats, CON + berberine control rats administrated with berberine, diabetic diabetic rats, diabetic + berberine diabetic rats 
administrated with berberine. Values are expressed as mean ± SEM and at least n = 10 cells recorded in each group. *P < 0.05 vs. CON rats and 
#P < 0.05 vs. diabetic rats
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CaL channels in plasma membrane and RyRs in SR 
are important mediators to control arterial excitation–
contraction coupling by handling intracellular Ca2+ in 
VSMCs. It is currently believed that when the membrane 
is depolarized, extracellular Ca2+ entries through CaL 
channels and then activates RyRs to produce the tran-
sient local Ca2+ release events, which is termed Ca2+-
induced Ca2+ release (CICR). This Ca2+ event not only 
contribute to the overall rise in the concentration of 
intracellular Ca2+, but also in turn activate nearby Ca2+-
activated K+ (KCa) channels in plasma membrane, lead-
ing to membrane hyperpolarization, inhibition of CaL 
channels, and thereby favoring vasodilation by reducing 
the Ca2+ influx. In the present work, the rat model of 
STZ-induced diabetic rats showed a higher blood glucose 
level (Table 1) and a significant increase in the contractile 
function of cerebral artery (Fig. 1) as compared with that 
in CON. In addition, the function of CaL channel (Figs. 3, 
5), the resting [Ca2+]i level (Fig. 6), and the Ca2+ releases 
from RyRs (Fig.  6) significantly increased in cerebral 
VSMCs isolated from STZ-induced diabetic rats. Fur-
thermore, we also observed that hyperglycemia directly 
increased the function of CaL channel (Fig.  8) and the 
Ca2+ releases from RyRs (Fig. 9) in cerebral VSMCs iso-
lated from normal control rats. All these results are in 
agreement with previous reports that hyperglycemia 
induced diabetic vascular dysfunction by elevating global 
intracellular calcium ([Ca2+]i) [4, 5], up-regulating the 
function of CaL channel [5, 22], and altering the function 
of Ca2+ releases from the RyRs [6, 24]. It is also reported 
that cardiac dysfunction in diabetic cardiomyopathy is 
associated with a time-dependent decline in Ca2+ sparks 
of diabetic SD rat [25]. However, overexpression of silent 
information regulator 1 (SIRT1) reduces diabetes-exacer-
bated injury of myocardial ischemia and reperfusion and 
oxidative stress [26]. In addition, corin, a cardiac serine 
protease, also exerts cardioprotective action via activat-
ing pro-atrial natriuretic peptide pathway in diabetic car-
diomyopathy [27].
The berberine treatment alleviates the cerebrovascular 
contractility in diabetic rats by regulating the intracellular 
Ca2+ handling in VSMCs
Berberine [18,  5,  6-dihydro-9,  10-dimethoxybenzo  (g)-
1,  3-benzodioxolo (5,  6-a) quinolizinium] is an 
isoquinoline alkaloid, which is extracted from berber-
ine-containing herbs, such as Goldenseal (Hydrastis 
canadensis), Oregon Grape (Berberis aquifolium), and 
Coptis chinensis (Chinese goldthread) [7]. It has been 
demonstrated that berberine exhibits a variety of phar-
macological properties and has been extensively used for 
the immune enhancement, antibacterial and antiparasitic 
effects, and gastrointestinal infections [12]. Recently, ber-
berine was found to have a long-term effect on lowering 
blood glucose, which could delay the diabetic compli-
cations in patients and various animal models [9]. The 
anti-hyperglycemic mechanisms of berberine are very 
complex, including the improving insulin secretion and 
sensitivity, activating the adenosine monophosphate-
activated protein kinase (AMPK) pathway, modulat-
ing gut microbiota, reducing intestinal absorption of 
glucose, inhibiting gluconeogenesis and glucose trans-
porter in liver, stimulating glycolysis in peripheral tissue 
cells [8, 12]. In addition, extensive studies indicated that 



























 100 mg/kg/d Berberine
a
b
Fig. 5 Comparison of α1C‑subunit expressions of CaL channel in 
cerebral arteries isolated from CON, CON +100 mg/kg/day berberine, 
diabetic, and diabetic +100 mg/kg/day berberine rats. Representa‑
tive band was used to show the protein expressions of CaL channel in 
different groups (a). Normalized band intensities are shown as a per‑
centage of the β‑actin density (b). Chronic administration of 100 mg/
kg/day berberine markedly reduced the augmented α1C‑subunit 
expressions of CaL channel in cerebral arteries isolated from diabetic 
rats. CON control rats, CON + berberine control rats administrated with 
berberine (100 mg/kg/day), Diabetic diabetic rats, Diabetic + ber-
berine diabetic rats administrated with berberine (100 mg/kg/day). 
Values are expressed as mean ± SEM from four independent experi‑
ments, and each sample based on tissue pooled from 3–4 animals. 
*P < 0.05 vs. CON rats and #P < 0.05 vs. diabetic rats
Page 12 of 17Ma et al. Cardiovasc Diabetol  (2016) 15:63 
 setebaiD NOC



































































































































 100 mg/kg/d Berberine
DiabetesCON






























) + 10 mM caffeine




























) + 10 mM caffeine
A
B
0 30 60 90 120 150 180
Fig. 6 Comparison of resting level of Ca2+ fluorescence intensity and maximal increases of Ca2+ fluorescence intensity in cerebral VSMCs isolated 
from CON, CON +100 mg/kg/day berberine, Diabetic, and diabetic +100 mg/kg/day berberine rats. Representative dot graph of Fluo‑3/AM fluores‑
cence recorded showed the typical transient increases of intracellular Ca2+ fluorescence intensity evoked by 10 mM caffeine (A). Summarized data 
indicated the average changes of the intracellular Ca2+ fluorescence intensity before and during the application of caffeine (B). Chronic adminis‑
tration of 100 mg/kg/day berberine significantly not only decreased the resting [Ca2+]i level, but also suppressed the Ca
2+ releases from RyRs in 
cerebral VSMCs isolated from diabetic rats. CON control rats, CON + berberine control rats administrated with berberine (100 mg/kg/day), Diabetic 
diabetic rats, diabetic + berberine diabetic rats administrated with berberine (100 mg/kg/day). Values are expressed as mean ± SEM and at least 
n = 10 cells recorded in each group. *P < 0.05 vs. CON rats and #P < 0.05 vs. diabetic rats
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diabetic cardiovascular complications. Besides the anti-
hyperglycemic and cholesterol-lowering activity, ber-
berine also has the anti-inflammatory and anti-oxidant 
properties to protect hyperglycemia-induced endothelial 
injury [10, 12]. For example, berberine could improve 
the endothelium-dependent vasodilatation by activation 
of the AMPK pathway [14], increasing the phosphoryla-
tion of endothelial nitric oxide synthase (eNOS) [15, 28], 
down-regulating expression of NADPH oxidase [13], and 
inhibiting the formation of advanced glycation end prod-
ucts (AGEs) [29]. It has been demonstrated that berber-
ine treatment attenuates palmitate-induced reduction in 
glucose uptake and consumption, in part, through reduc-
tion in cellular 1,2-diacyl-sn-glycerol (DAG) levels and 
accumulation of 1,2,3-triacyl-sn-glycerol (TAG) in H9c2 
cells [30].
In the present work, chronic administration of 100 mg/
kg/day berberine not only significantly reduced glucose 
levels in diabetic rats (Table 1), but also markedly inhib-
ited the augmented contractile function of cerebral artery 
in diabetic rats (Fig.  1). In addition, chronic adminis-
tration of 100  mg/kg/day berberine not only markedly 
inhibited the increased CaL channel current densities 
(Fig.  3), but also reduced the augmented α1C-subunit 
expressions of CaL channel (Fig.  5) in cerebral VSMCs 
isolated from diabetic rats. Furthermore, 100  mg/kg/
day chronic administration of berberine not only mark-
edly decreased the increased resting [Ca2+]i level, but 
also suppressed the augmented Ca2+ releases from RyRs 
(Fig.  6) in cerebral VSMCs isolated from diabetic rats. 
Correspondingly, acute application of berberine could 
directly inhibit the hyperglycemia-induced CaL currents 
(Fig.  8) and suppress the hyperglycemia-induced Ca2+ 
releases from RyRs (Fig.  9) in cerebral VSMCs isolated 
from normal control rats. Our results suggested 100 mg/
kg/day berberine treatment could alleviate the cerebral 
arterial contractility by regulating the intracellular Ca2+ 
handling of VSMCs in diabetic rats or when exposed to 
hyperglycemia condition.
From our results, chronic administration of 50  mg/
kg/day berberine had no obvious effects on contractile 
responsiveness (Fig. 2), CaL peak current density (Fig. 4), 
and maximal increases of Ca2+ fluorescence intensity 
(Fig.  7) in CON and Diabetic rats, respectively. How-
ever, chronic administration of 200  mg/kg/day berber-
ine significantly inhibited the contractile responsiveness 
(Fig.  2), CaL peak current density (Fig.  4), and maximal 
increases of Ca2+ fluorescence intensity (Fig.  7) in both 
CON and diabetic rats, respectively. We concluded that 
the dose of berberine is very important for treatment 
and 100  mg/kg/day berberine could produce significant 
effects on DM rats rather than CON rats in terms of con-
tractile function, CaL channel and [Ca2+]i.
Practical implications of the present study
It has been reported that several therapeutic strate-
gies are administered to ameliorate the deteriorated 
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DiabetesCON
Fig. 7 Comparison of maximal increases of Ca2+ fluorescence intensity in response to different dose of berberine (50 and 200 mg/kg/day) in 
cerebral VSMCs isolated from CON, CON + berberine, Diabetic, and diabetic + berberine rats. Chronic administration of 50 mg/kg/day berberine 
had no obvious effects on maximal increases of Ca2+ fluorescence intensity in CON and diabetic rats, respectively. In addition, chronic administra‑
tion of 200 mg/kg/day berberine significantly inhibited the Ca2+ releases from RyRs in both CON and diabetic rats, respectively. CON control rats, 
CON + berberine control rats administrated with berberine, Diabetic diabetic rats, diabetic + berberine diabetic rats administrated with berberine. 
Values are expressed as mean ± SEM and at least n = 8 cells recorded in each group. *P < 0.05 vs. CON rats and #P < 0.05 vs. diabetic rats
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endothelium-dependent NO production, reducing 
the oxidative stress damage, inhibiting the inflam-
matory responses [7, 8]. Our study may provide a 
novel therapeutic approach to treat vascular dysfunc-
tion in diabetic patients by regulating the intracellular 
Ca2+ handling with their related proteins in VSMCs. 
In addition, the safety and efficacy of berberine have 
been generally accepted as a kind of traditional Chi-
nese medicine. It is believed that berberine performs 
a good clinical practice and our study provided new 
evidence that application of berberine is a novel poten-
tial application in the treatment of diabetic vascular 
dysfunction.
Study limitations
First, there are some disparities between our work and 
other previous reports. The present work showed that 
the function of CaL channel significantly increased in 
the rat model of STZ-induced diabetic rats (Figs. 3, 5) 
or when exposed to hyperglycemia condition (Fig.  8), 
which are in consistence with previous reports [5, 22]. 
However, there is also a report that CaL channel cur-
rents significantly reduced in STZ-induced diabetic 
rats [3]. In addition, we observed that Ca2+ releases 
from RyRs significantly increased in the diabetic rats 
(Fig.  6) or when exposed to hyperglycemia condition 
(Fig.  9), which are in agreement with previous report 
that there was a dramatic increase in ryanodine recep-
tor (RyR) levels of VSMCs from diabetic animals [6]. 
However, reduced expression of RyR has also been 
reported in several diabetic models [3]. These dis-
crepancies may be related to different species or rat 
strain, the method of diabetic induction, the vascular 
bed studied or the severity of diabetes [3, 31]. Sec-
ond, RyRs and inositol 1,4,5-trisphosphate receptors 
(IP3Rs) are the two mainly important families of Ca2+ 
release channels in the SR. Activation of IP3Rs could 
also evoke the localized Ca2+ transients and contribute 
to the global elevation of intracellular Ca2+. Thus, it is 
necessary to study the role of IP3Rs in the berberine 
treatment for the diabetic vascular dysfunction. Third, 
we observed that berberine inhibited the function of 
CaL channel in the present work. However, the pre-
sent work did not study the underlying mechanism. It 
is believed that there are three subclasses of calcium 
channel blockers which are wildly used to block CaL 
channel by binding to the poreforming α1C subunit, 
such as dihydropyridine, phenylalkylamine, and ben-
zothiazepine. Whether berberine inhibited the func-
tion of CaL channel by directly binding to poreforming 
α1C subunit or other indirect pathway needs the fur-
ther investigation.
Conclusion
The present work showed that berberine treatment could 
alleviate the cerebral arterial contractility independent 
of a functional endothelium in the rat model of strep-







































































Fig. 8 Acute application of berberine directly inhibited the hypergly‑
cemia‑induced CaL currents in cerebral VSMCs isolated from normal 
control rats. Representative traces of CaL channel current at +10 mV 
in cerebral VSMCs when exposed to 20 mM d‑glucose and then 
subsequent acute application of 10 μM berberine in the presence 
of 20 mM d‑glucose. At last, the cerebral VSMCs were washed with 
20 mM d‑glucose (a). Summarized data indicated the amplitudes of 
CaL channel current at +10 mV before and after application of 20 mM 
d‑glucose, 10 μM berberine in the presence of 20 mM d‑glucose, and 
then washing with 20 mM d‑glucose (b). Values are mean ± SEM with 
the number of cells recorded in parentheses. *P < 0.05 vs. control 
condition and #P < 0.05 vs. high glucose condition
Page 15 of 17Ma et al. Cardiovasc Diabetol  (2016) 15:63 
Berberine (10 µM) + D-glucose (20 mM) 
























































































+ 10 mM Caffeine
b
0 30 60 90 120 150 180































+ 10 mM caffeine















































































































0 30 60 90 120 150 180
0 20 40 60 80 100 120 140 160 180
Fig. 9 Acute application of berberine directly suppressed the hyperglycemia‑induced Ca2+ releases from RyRs in cerebral VSMCs isolated from 
normal control rats. Typical transient increases of intracellular Ca2+ evoked by 10 mM caffeine were recorded when cerebral VSMCs exposed to the 
20 mM d‑glucose or the combination of 10 μM berberine and 20 mM d‑glucose, respectively. At last, the cerebral VSMCs were washed with 20 mM 
d‑glucose (a). Summarized data indicated the average changes of the resting intracellular Ca2+ and Ca2+ releases from RyRs before and after appli‑
cation of the 20 mM d‑glucose and the combination of 10 μM berberine and 20 mM d‑glucose, respectively (b). Values are mean ± SEM with the 
number of cells recorded in parentheses. *P < 0.05 vs. control condition and #P < 0.05 vs. high glucose condition
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treatment not only directly inhibited the function of 
CaL channels, but also suppressed the function of Ca2+ 
releases from the RyRs of cerebral VSMCs in diabetic 
rats or when exposed to hyperglycemia condition. Taken 
together, our study indicated that berberine alleviated the 
cerebral arterial contractility in the rat model of strepto-
zotocin-induced  diabetes via regulating the intracellular 
Ca2+ handling of smooth muscle cells.
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